Sustained margin improvement dependent on product mix
Management acknowledged that quarterly margins are influenced by product mix and cannot be guaranteed, though year-on-year improvement is targeted.
HESTERBIO / bear-case history
Track the concerns that keep returning.
Hester Biosciences · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
medium
Delays in government immunization programs
Animal health division revenue declined 38% due to delayed PPR and goatpox programs; recovery depends on timely execution starting February 2026.
Africa revenue dependent on funding releases
Africa operations rely on multilateral funding and country-level rollout timelines, which can cause execution delays.
Nepal operations facing challenging phase
Management noted Nepal operations are in a challenging phase and are evaluating measures for stability and sustainability.
Tender timing volatility in animal healthcare
Animal healthcare revenue fell 30% YoY due to delayed government tenders; recovery depends on timely rollout.
Rising raw material costs
Global geopolitical developments and supply chain disruptions are increasing raw material costs, pressuring margins.
High receivables and working capital
Receivables of ₹92 crore on ~₹300 crore revenue are elevated; Q4 sales spike contributed but management is working to reduce days.
Regulatory changes requiring additional capex
Evolving regulatory requirements may necessitate further capital allocation, though management did not quantify.